Strategies for developing PD-1 inhibitors and future directions

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• The PD-1/PD-L1 signaling pathway is a critical target for cancer therapeutics.
• Inhibitors targeting PD-1, PD-L1, or their interaction have been developed.
• Understanding the PD-1 pathway and its regulation offers diverse drug design strategies.

Purpose of the Study:

• To review current strategies for developing drugs targeting the PD-1/PD-L1 pathway.
• To discuss the structural, signaling, and regulatory aspects of PD-1/PD-L1.
• To propose future directions for PD-1/PD-L1 inhibitor development.

Main Methods:

• Review of literature on PD-1/PD-L1 structure, signaling, and post-translational modifications.
• Analysis of existing and emerging therapeutic strategies targeting the PD-1/PD-L1 pathway.
• Exploration of novel approaches like bifunctional molecules and siRNA-based nanomedicine.

Main Results:

• Elucidation of PD-1/PD-L1 crystal structure enables targeted inhibitor design.
• Interference with PD-1 signaling, such as SHP2 recruitment inhibition, is a viable strategy.
• Post-translational modifications and protein-degrading reagents offer additional therapeutic avenues.

Conclusions:

• Future PD-1/PD-L1 inhibitor development may focus on multifunctional small molecules and siRNA-loaded nanomaterials.
• Simultaneous targeting of PD-1 and other T-cell checkpoints via nanomedicine holds significant promise for cancer immunotherapy.
• Targeting the tumor microenvironment with advanced delivery systems can enhance T-cell mediated immunity.